WO1993014083A1 - Derives de benzimidazole substitues pharmaceutiquement actifs - Google Patents
Derives de benzimidazole substitues pharmaceutiquement actifs Download PDFInfo
- Publication number
- WO1993014083A1 WO1993014083A1 PCT/EP1992/003006 EP9203006W WO9314083A1 WO 1993014083 A1 WO1993014083 A1 WO 1993014083A1 EP 9203006 W EP9203006 W EP 9203006W WO 9314083 A1 WO9314083 A1 WO 9314083A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- compound
- alkyl
- radical
- optionally substituted
- Prior art date
Links
- 229940058303 antinematodal benzimidazole derivative Drugs 0.000 title 1
- 125000003785 benzimidazolyl group Chemical class N1=C(NC2=C1C=CC=C2)* 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 149
- -1 C1-6alkyloxy Chemical group 0.000 claims abstract description 51
- 239000001257 hydrogen Substances 0.000 claims abstract description 50
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 50
- 239000000203 mixture Substances 0.000 claims abstract description 42
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 25
- 238000000034 method Methods 0.000 claims abstract description 25
- 125000003118 aryl group Chemical group 0.000 claims abstract description 21
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 19
- 229910052717 sulfur Inorganic materials 0.000 claims abstract description 16
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract description 7
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims abstract description 4
- 125000005129 aryl carbonyl group Chemical group 0.000 claims abstract description 3
- 239000002253 acid Substances 0.000 claims description 29
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 28
- 150000003839 salts Chemical class 0.000 claims description 24
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 22
- 150000002431 hydrogen Chemical group 0.000 claims description 20
- 239000003054 catalyst Substances 0.000 claims description 17
- 238000006243 chemical reaction Methods 0.000 claims description 16
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 14
- 239000003153 chemical reaction reagent Substances 0.000 claims description 13
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 13
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 11
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 11
- 239000002585 base Substances 0.000 claims description 10
- 125000001424 substituent group Chemical group 0.000 claims description 10
- 125000004432 carbon atom Chemical group C* 0.000 claims description 8
- 150000002576 ketones Chemical class 0.000 claims description 8
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 8
- 238000005804 alkylation reaction Methods 0.000 claims description 7
- 230000002152 alkylating effect Effects 0.000 claims description 6
- 239000000010 aprotic solvent Substances 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 6
- 125000000335 thiazolyl group Chemical group 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 125000000524 functional group Chemical group 0.000 claims description 5
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims description 4
- 150000001299 aldehydes Chemical class 0.000 claims description 4
- 239000003513 alkali Substances 0.000 claims description 4
- 239000012298 atmosphere Substances 0.000 claims description 4
- 239000012948 isocyanate Substances 0.000 claims description 4
- 150000002513 isocyanates Chemical class 0.000 claims description 4
- 150000002540 isothiocyanates Chemical class 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- 125000002971 oxazolyl group Chemical group 0.000 claims description 4
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 4
- 125000004076 pyridyl group Chemical group 0.000 claims description 4
- 239000012312 sodium hydride Substances 0.000 claims description 4
- 229910000104 sodium hydride Inorganic materials 0.000 claims description 4
- 125000001544 thienyl group Chemical group 0.000 claims description 4
- 230000009466 transformation Effects 0.000 claims description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims description 3
- 101000598009 Labrenzia aggregata (strain ATCC 25650 / DSM 13394 / JCM 20685 / NBRC 16684 / NCIMB 2208 / IAM 12614 / B1) Isatin hydrolase Proteins 0.000 claims description 3
- 150000004945 aromatic hydrocarbons Chemical class 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- 239000012458 free base Substances 0.000 claims description 3
- 125000005059 halophenyl group Chemical group 0.000 claims description 3
- 125000002883 imidazolyl group Chemical group 0.000 claims description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 3
- 150000007530 organic bases Chemical class 0.000 claims description 3
- 239000002574 poison Substances 0.000 claims description 3
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 claims description 2
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 2
- 229910000288 alkali metal carbonate Inorganic materials 0.000 claims description 2
- 150000008041 alkali metal carbonates Chemical class 0.000 claims description 2
- 150000001336 alkenes Chemical class 0.000 claims description 2
- 238000005984 hydrogenation reaction Methods 0.000 claims description 2
- 239000003960 organic solvent Substances 0.000 claims description 2
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 2
- 125000001475 halogen functional group Chemical group 0.000 claims 12
- 230000003266 anti-allergic effect Effects 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 3
- 150000002118 epoxides Chemical class 0.000 claims 2
- 125000002541 furyl group Chemical group 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 1
- 239000000543 intermediate Substances 0.000 abstract description 27
- 238000002360 preparation method Methods 0.000 abstract description 14
- 230000001387 anti-histamine Effects 0.000 abstract description 10
- 239000000739 antihistaminic agent Substances 0.000 abstract description 6
- 208000026935 allergic disease Diseases 0.000 abstract description 4
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 abstract description 2
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 abstract 1
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 41
- 150000003254 radicals Chemical class 0.000 description 32
- 239000000243 solution Substances 0.000 description 29
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 27
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 19
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 17
- 125000005843 halogen group Chemical group 0.000 description 16
- 239000000047 product Substances 0.000 description 16
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
- 239000011541 reaction mixture Substances 0.000 description 15
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 14
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 238000004440 column chromatography Methods 0.000 description 11
- 239000003480 eluent Substances 0.000 description 11
- 239000000741 silica gel Substances 0.000 description 11
- 229910002027 silica gel Inorganic materials 0.000 description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- 238000003756 stirring Methods 0.000 description 10
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical class OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 9
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 9
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 9
- 230000002829 reductive effect Effects 0.000 description 9
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 8
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 8
- 239000003826 tablet Substances 0.000 description 8
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 7
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 7
- 238000007126 N-alkylation reaction Methods 0.000 description 7
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
- 239000012442 inert solvent Substances 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 5
- 150000007513 acids Chemical class 0.000 description 5
- 229960001701 chloroform Drugs 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical compound [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 0 C*(C(*)C(C(N(**)C1=**=*)=NC1=*)=C)C1CC1 Chemical compound C*(C(*)C(C(N(**)C1=**=*)=NC1=*)=C)C1CC1 0.000 description 3
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000007868 Raney catalyst Substances 0.000 description 3
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 3
- 229910000564 Raney nickel Inorganic materials 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 229940125715 antihistaminic agent Drugs 0.000 description 3
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 3
- 150000008282 halocarbons Chemical class 0.000 description 3
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 3
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 3
- 150000002924 oxiranes Chemical class 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000000376 reactant Substances 0.000 description 3
- 238000006722 reduction reaction Methods 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 125000001246 bromo group Chemical group Br* 0.000 description 2
- BRPQOXSCLDDYGP-UHFFFAOYSA-N calcium oxide Chemical compound [O-2].[Ca+2] BRPQOXSCLDDYGP-UHFFFAOYSA-N 0.000 description 2
- 239000000292 calcium oxide Substances 0.000 description 2
- 235000012255 calcium oxide Nutrition 0.000 description 2
- 229940087373 calcium oxide Drugs 0.000 description 2
- ODINCKMPIJJUCX-UHFFFAOYSA-N calcium oxide Inorganic materials [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 229920002055 compound 48/80 Polymers 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 231100000225 lethality Toxicity 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 2
- RPNNPZHFJPXFQS-UHFFFAOYSA-N methane;rhodium Chemical compound C.[Rh] RPNNPZHFJPXFQS-UHFFFAOYSA-N 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920000137 polyphosphoric acid Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 2
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 229960003415 propylparaben Drugs 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 229930195734 saturated hydrocarbon Natural products 0.000 description 2
- 238000010956 selective crystallization Methods 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- ILJOYZVVZZFIKA-UHFFFAOYSA-M sodium;1,1-dioxo-1,2-benzothiazol-3-olate;hydrate Chemical compound O.[Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 ILJOYZVVZZFIKA-UHFFFAOYSA-M 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
- CUJPFPXNDSIBPG-UHFFFAOYSA-N 1,3-propanediyl Chemical group [CH2]C[CH2] CUJPFPXNDSIBPG-UHFFFAOYSA-N 0.000 description 1
- IJVLVRYLIMQVDD-UHFFFAOYSA-N 1,3-thiazole-2-carboxylic acid Chemical compound OC(=O)C1=NC=CS1 IJVLVRYLIMQVDD-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- OMIVCRYZSXDGAB-UHFFFAOYSA-N 1,4-butanediyl Chemical group [CH2]CC[CH2] OMIVCRYZSXDGAB-UHFFFAOYSA-N 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- ZYHQGITXIJDDKC-UHFFFAOYSA-N 2-[2-(2-aminophenyl)ethyl]aniline Chemical group NC1=CC=CC=C1CCC1=CC=CC=C1N ZYHQGITXIJDDKC-UHFFFAOYSA-N 0.000 description 1
- XYQRDQDBXFIBMF-UHFFFAOYSA-N 2-[4-[1-[1-[(4-fluorophenyl)methyl]benzimidazol-2-yl]ethenyl]piperidin-1-yl]ethanol Chemical compound C1CN(CCO)CCC1C(=C)C1=NC2=CC=CC=C2N1CC1=CC=C(F)C=C1 XYQRDQDBXFIBMF-UHFFFAOYSA-N 0.000 description 1
- PGXALMVNIRPELS-UHFFFAOYSA-N 2-chloro-1-[(4-fluorophenyl)methyl]benzimidazole Chemical compound C1=CC(F)=CC=C1CN1C2=CC=CC=C2N=C1Cl PGXALMVNIRPELS-UHFFFAOYSA-N 0.000 description 1
- KBHRQIXRVHFRPF-UHFFFAOYSA-M 2-chloro-1-methylpyridin-1-ium;chloride Chemical compound [Cl-].C[N+]1=CC=CC=C1Cl KBHRQIXRVHFRPF-UHFFFAOYSA-M 0.000 description 1
- UNCQVRBWJWWJBF-UHFFFAOYSA-N 2-chloropyrimidine Chemical compound ClC1=NC=CC=N1 UNCQVRBWJWWJBF-UHFFFAOYSA-N 0.000 description 1
- ASVZBRLVGGMTEN-UHFFFAOYSA-N 2-methylidenebenzimidazole Chemical compound C1=CC=CC2=NC(=C)N=C21 ASVZBRLVGGMTEN-UHFFFAOYSA-N 0.000 description 1
- WTMQOVJAJZXMJC-UHFFFAOYSA-N 2-methylideneimidazo[4,5-b]pyridine Chemical class C1=CC=NC2=NC(=C)N=C21 WTMQOVJAJZXMJC-UHFFFAOYSA-N 0.000 description 1
- 125000006024 2-pentenyl group Chemical group 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-M 4-hydroxybenzoate Chemical compound OC1=CC=C(C([O-])=O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-M 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 238000006027 Birch reduction reaction Methods 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 230000006181 N-acylation Effects 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- KFZBGOCMTGOSHR-UHFFFAOYSA-N OC=C1N=C2C(=N1)C=CC=C2 Chemical class OC=C1N=C2C(=N1)C=CC=C2 KFZBGOCMTGOSHR-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-L Oxalate Chemical compound [O-]C(=O)C([O-])=O MUBZPKHOEPUJKR-UHFFFAOYSA-L 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 235000002357 Ribes grossularia Nutrition 0.000 description 1
- 244000171263 Ribes grossularia Species 0.000 description 1
- 240000007651 Rubus glaucus Species 0.000 description 1
- 235000011034 Rubus glaucus Nutrition 0.000 description 1
- 235000009122 Rubus idaeus Nutrition 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- 206010052568 Urticaria chronic Diseases 0.000 description 1
- AKZWRTCWNXHHFR-PDIZUQLASA-N [(3S)-oxolan-3-yl] N-[(2S,3S)-4-[(5S)-5-benzyl-3-[(2R)-2-carbamoyloxy-2,3-dihydro-1H-inden-1-yl]-4-oxo-3H-pyrrol-5-yl]-3-hydroxy-1-phenylbutan-2-yl]carbamate Chemical compound NC(=O)O[C@@H]1Cc2ccccc2C1C1C=N[C@](C[C@H](O)[C@H](Cc2ccccc2)NC(=O)O[C@H]2CCOC2)(Cc2ccccc2)C1=O AKZWRTCWNXHHFR-PDIZUQLASA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 238000007259 addition reaction Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910001516 alkali metal iodide Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 150000004703 alkoxides Chemical class 0.000 description 1
- 201000009961 allergic asthma Diseases 0.000 description 1
- 208000002205 allergic conjunctivitis Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 229940082988 antihypertensives serotonin antagonists Drugs 0.000 description 1
- 239000003420 antiserotonin agent Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000024998 atopic conjunctivitis Diseases 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000024376 chronic urticaria Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000005906 dihydroxylation reaction Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- QHSHDVYEJKLXLB-UHFFFAOYSA-N ethyl n-(2-chloroethyl)carbamate Chemical compound CCOC(=O)NCCCl QHSHDVYEJKLXLB-UHFFFAOYSA-N 0.000 description 1
- IFYLVUHLOOCYBG-UHFFFAOYSA-N eticyclidine Chemical compound C=1C=CC=CC=1C1(NCC)CCCCC1 IFYLVUHLOOCYBG-UHFFFAOYSA-N 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 229940052308 general anesthetics halogenated hydrocarbons Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 238000007327 hydrogenolysis reaction Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-M iodide Chemical compound [I-] XMBWDFGMSWQBCA-UHFFFAOYSA-M 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 229940098462 oral drops Drugs 0.000 description 1
- 229940100688 oral solution Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 238000003408 phase transfer catalysis Methods 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 229920006324 polyoxymethylene Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 239000011698 potassium fluoride Substances 0.000 description 1
- 235000003270 potassium fluoride Nutrition 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 125000001844 prenyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 1
- JADFCQKRKICRKI-UHFFFAOYSA-N quinoline;sulfane Chemical compound S.N1=CC=CC2=CC=CC=C21 JADFCQKRKICRKI-UHFFFAOYSA-N 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000004544 spot-on Substances 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Definitions
- the present invention is concerned with novel 4-piperidinyl derivatives having the formula :
- radicals (a-1) to (a-7) may each independently be replaced by halo, Ci-6alkyl, Ci ⁇ alkyloxy, hydroxy ortrifluoro- methyl;
- R 1 is Ar or a radical of formula -D-R 2 wherein D is O or S;
- R 2 is Ci- ⁇ alkyl optionally substituted with hydroxy, Ci- alkyloxy, carboxyl or Ci ⁇ alkyloxycarbonyl; m is 1, 2, 3 or 4; n is 0, 1 or 2 ;
- L is hydrogen; Ci ⁇ a-U yl; C3- ⁇ cycloalkyl; C3 ⁇ alkenyl optionally substituted with aryl; C ⁇ alkylcarbonyl; Cx-.galkyloxycarbonyl; arylcarbonyl; arylC ⁇ alkyloxy- carbonyl; or a radical of formula :
- Alk is Ci-6alkanediyl
- R 3 is cyano, aryl or Het
- R 4 is hydrogen, aryl, Het or Ci-6alkyl optionally substituted with aryl or Het;
- R 5 is hydrogen, aryl, Het or Ci- ⁇ alkyl optionally substituted with aryl or Het
- R 6 is aryl ornaphthalenyl
- Y is O, S, NR 7 ; said R 7 being hydrogen, Ci ⁇ alkyl or Ci ⁇ alkylcarbonyl ; Z 1 and Z 2 each independently are O, S, NR 8 or a direct bond; said R 8 being hydrogen or C ⁇ --6alkyl;
- T is O, S or NR 9 ; said R 9 being hydrogen, Ci- ⁇ alkyl or cyano;
- each Het is selected from pyridinyl optionally substituted with one or two substituents each independently selected from halo, amino, mono- and di(C ⁇ alkyl)amino, nitro, cyano, Ci ⁇ alkyl, Ci ⁇ alkyloxy and hydroxy; pyrimidinyl optionally substituted with one or two substituents each independently selected from halo, amino, Ci-6alkylamino, Ci-6alkyl and C ⁇ --6alkyloxy; pyridazinyl optionally substituted with Ci ⁇ alkyl or halo; pyrazinyl optionally substituted with halo, amino or Ci ⁇ alkyl; thienyl optionally substituted with halo or Ci-6alkyl; fiiranyl optionally substituted with halo or Ci- ⁇ alkyl; pyrrolyl optionally substituted with Ci ⁇ alkyl; thiazolyl optionally substituted with Ci-ealkyl; imidazolyl optionally substituted with one or two
- X 1 and X 2 each independently are O or S ; each R 10 is hydrogen, Ci- ⁇ alkyl, arylCi- ⁇ alkyl, C ⁇ alkyloxyC ⁇ .-6alkyl, hydroxy-
- R 11 is hydrogen, Ci ⁇ alkyl, hydroxy, mercapto, Ci-6alkyloxy, Ci- ⁇ alkylthio, halo or 15 Ci-6alkyloxycarbonylCi-6alkyl ;
- radicals G 1 , G 2 , G 3 or G 4 may be replaced by or halo, when connected to a carbon atom; or by Ci ⁇ alkyl, C ⁇ --6alkyloxycarbonyl or arylCi- ⁇ alkyl when connected to a nitrogen atom; and
- X * r rQ — is a radical having the formula
- each aryl is phenyl optionally substituted with 1, 2 or 3 substituents each independently selected from halo, hydroxy, nitro, cyano, trifluoromethyl, Ci ⁇ alkyl, Ci ⁇ alkyloxy, Ci ⁇ alkylthio, mercapto, amino, mono- and di(Ci-6alkyl)amino, carboxyl, Ci ⁇ alkyloxycarbonyl and Ci-6alkylcarbonyl;
- Ar is phenyl optionally substituted with 1, 2 or 3 substituents each independently selected from halo, hydroxy, nitro, cyano, trifluoromethyl, Ci ⁇ alkyl, Ci-galkyloxy, C ⁇ --6alkylthio, mercapto, amino, mono- and di(C ⁇ --6aIkyl)amino, carboxyl, Ci ⁇ alkyloxycarbonyl and Ci ⁇ alkylcarbonyl; thienyl; halothienyl; fiiranyl optionally substituted with Ci ⁇ alkyl and/or hydroxyCi ⁇ alkyl; oxazolyl optionally substituted with Ci- ⁇ alkyl and/or hydroxyCi ⁇ alkyl; pyridinyl optionally substituted with Ci- ⁇ alkyl; pyrimidinyl; pyrazinyl; thiazolyl optionally substituted with Ci ⁇ alkyl; orimidazolyl optionally substituted with C ⁇ -- 6 alkyl.
- halo is generic to fluoro, chloro, bromo and iodo
- C ⁇ -_5alkyl defines straight and branch chained saturated hydrocarbon radicals having from 1 to 6 carbon atoms such as, for example, methyl, ethyl, propyl, 1-methylethyl, butyl, 1,1-dimethylethyl, 1-methylpropyl, 2-methylpropyl, pentyl, hexyl and the like
- Ci- ⁇ 2 alkyl defines Ci- ⁇ alkyl radicals as defined hereinabove and the higher homologs thereof having from 7 to 12 carbon atoms
- C3 ⁇ cycloalkyl is generic to cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl
- C3 ⁇ alkenyl defines straight and branch chained hydrocarbon radicals containing one double bond and having from 3 to 6 carbon atoms such as, for example, 2-propenyl, 3-buten
- the pharmaceutically acceptable acid addition salts as mentioned hereinabove comprise the therapeutically active non-toxic acid addition salt forms which the compounds of formula (I) are able to form.
- Said salt forms can conveniently be obtained by treating the base form of the compounds of formula (I) with appropriate acids such as inorganic acids, for example, hydrohalic acid, e.g.
- hydrochloric, hydrobromic and the like acids sulfuric acid, nitric acid, phosphoric acid and the like; or organic acids, such as, for example, acetic, propanoic, hydroxyacetic, 2-hydroxypropanoic, 2-oxopro- panoic, ethanedioic, propanedioic, butanedioic, (Z)-2-butenedioic, (E)-2-butenedioic, 2-hydroxybutanedioic, 2,3-dihydroxybutanedioic, 2-hydroxy- 1 ,2,3-propanetri- carboxylic, methanesulfonic, ethanesulfonic, benzenesulfonic, 4-methylbenzene- sulfonic, cyclohexanesulfamic, 2-hydroxybenzoic, 4-amino-2-hydroxybenzoic and the like acids.
- the salt form can be converted by treatment with alkali into the free base form.
- acid addition salt also comprises the hydrates and solvent addition forms which the compounds of formula (I) are able to form. Examples of such forms are e.g. hydrates, alcoholates and the like.
- the compounds of this invention may have several asymmetric carbon atoms in their structure. As usual, each of these chiral centers may be indicated by the stereochemical descriptors R and S. The stereochemically isomeric forms of the compounds of formula (I) are obviously intended to be included within the scope of the invention.
- More interesting compounds are those interesting compounds wherein X — Q — is
- R-" is C ⁇ alkyl
- R 4 is hydrogen or pyrimidinyl
- Y is O orNH
- R 5 is Ci ⁇ alkyl, aminophenyl or thiazolyl
- Z 1 and Z 2 each independently are O, NH or a direct bond and T is O or S.
- R 1 * is methyl
- R 4 is hydrogen or 2-pyrimidinyl
- Y is O or NH
- R 5 is Ci ⁇ alkyl, 2-aminophenyl or 2-thiazolyl
- Z 1 is NH
- Z 2 is NH or a direct bond
- T is O or S.
- R 5 is methyl or 2-thiazolyl;
- Z 1 is NH,
- Z 2 is NH or a direct bond and T is O or S.
- said compounds being represented by formula (I-b) can be prepared by dehydration of an intermediate of formula (Ill-a) or (EQ-b) in the presence of an acid.
- Suitable acids are for example (poly)phosphoric acid, sulfuric acid, methanesulfonic acid, trifluoromethanesulfonic acid and the like.
- the compounds of formulae (I-a) and (I- b) may also be obtained by refluxing an intermediate of formula (Il-a), (Ill-a) or (IH-b) in hexamethylphosphoric triamide.
- the compounds of formula (I-b) can be reduced by catalytic hydrogenation in a suitable solvent, e.g. methanol or ethanol, in the presence of hydrogen and an appropriate catalyst, e.g. platinum-on-charcoal, palladium-on-charcoal, Raney nickel and the like, optionally at an increased temperature and/or pressure.
- a suitable solvent e.g. methanol or ethanol
- an appropriate catalyst e.g. platinum-on-charcoal, palladium-on-charcoal, Raney nickel and the like, optionally at an increased temperature and/or pressure.
- Some compounds of formula (I-c) may also be obtained by catalytic dehydroxylation of an intermediate of formula (Hl-a) or (Ul-b) following art-known procedures.
- the compounds of formula (I) wherein L is other than hydrogen, said L being represented by l ⁇ and said compounds being represented by formula (I-d) can be prepared by H-alkylating a compound of formula (I) wherein L is hydrogen, said compound being represented by (I-e), with an alkylating reagent of formula (IN).
- W represents an appropriate leaving group such as, for example, halo, e.g. chloro, bromo and the like; or a sulfonyloxy group such as, for example, methanesulfonyloxy , 4-methylbenzenesulfonyloxy and the like.
- Said N-alkylation reaction can conveniently be conducted in a reaction-inert solvent such as, for example, water, an aromatic hydrocarbon, an alkanol, a ketone, an ether, a dipolar aprotic solvent, or a mixture of such solvents.
- a reaction-inert solvent such as, for example, water, an aromatic hydrocarbon, an alkanol, a ketone, an ether, a dipolar aprotic solvent, or a mixture of such solvents.
- an appropriate base such as, for example, an alkali or an earth alkaline metal carbonate, hydrogen carbonate, alkoxide, hydride, amide, hydroxide or oxide
- an organic base such as, for example, an amine
- an iodide salt preferably an alkali metal iodide, is appropriate.
- N_-alkylation may be conducted under an inert atmosphere such as, for example, oxygen-free argon or nitrogen.
- said £J-alkylation may be carried out by applying art-known conditions of phase transfer catalysis reactions.
- Said reductive N-alkylation reaction may conveniently be carried out by reducing a mixture of the reactants in a suitable reaction-inert solvent following art-known reductive N-alkylation procedures.
- the reaction mixture may be stirred and/or heated in order to enhance the reaction rate.
- Suitable solvents are, for example, water; Ci ⁇ alkanols, esters, ethers, halogenated hydrocarbons, dipolar aprotic solvents, carboxylic acids, or a mixture of such solvents.
- the term "art-known reductive N-alkylation procedures” means that the reaction is carried out either with sodium cyanoborohydride, sodium borohydride, formic acid or a salt thereof, e.g.
- ammonium formate and the like reducing agents or alternatively under hydrogen atmosphere, optionally at an increased temperature and/or pressure, in the presence of an appropriate catalyst such as, for example, palladium-on-charcoal, platinum-on-charcoal and the like.
- an appropriate catalyst such as, for example, palladium-on-charcoal, platinum-on-charcoal and the like.
- an appropriate catalyst-poison e.g., thiophene, quinoline-sulphur and the like.
- an alkali metal salt to the reaction mixture such as, for example, potassium fluoride, potassium acetate and the like salts.
- the compounds of formula (I) wherein L is 2-hydroxyC2-6alkyl or a radical of formula (b-4), said compounds being represented by formula (I-d-3), can be prepared by reacting a compound of formula (I-e) with an epoxide (VII) wherein R* 2 is hydrogen, C ⁇ _4alkyl or a radical R 6 -O-CH2-.
- reaction of (I-e) with respectively (VI) and (VII) may be conducted by stirring and, if desired, heating the reactants in a reaction-inert solvent such as, for example, a ketone, e.g., 2-propanone, 4-methyl-2-pentanone, an ether, e.g., tetrahydrofuran, l,l'-oxybisethane, an alcohol, e.g., methanol, ethanol, 1-butanol, a dipolar aprotic solvent, e.g., N,N-dimethylformamide, N_,N-dimethylacetamide and the like.
- a reaction-inert solvent such as, for example, a ketone, e.g., 2-propanone, 4-methyl-2-pentanone, an ether, e.g., tetrahydrofuran, l,l'-oxybisethane, an alcohol, e.g., methanol, ethanol,
- the compounds of formula (I) can also be prepared by N.-alkylating an intermediate of formula (VIII) with an appropriate alkylating reagent of formula (IX).
- N-alkylation is conveniently conducted following art-known N-alkylation procedures as described hereinabove for the preparation of (I-d) from (I-e) and (IV).
- the compounds of formula (I) wherein L is a radical of formula (b-2) and R ⁇ is aiyl or Het, said R ⁇ being represented by R 4 " a and said compounds by formula (I-d-4) may • also be prepared by alkylating a compound of formula (I) wherein L is a radical of formula (b-2) and R ⁇ is hydrogen, said compound being represented by formula (I-d-5), with a reagent of formula (X-a) .
- the compounds of formula (I-d-4) may also be prepared by treating a compound of formula (XI) with a reagent of formula (X-b).
- the alkylation reactions of (I-d-5) with (X-a) and (X-b) with (XI) may conveniently be conducted in an inert organic solvent such as, for example, an aromatic hydrocarbon, a ketone, an ether, an alcohol, or a dipolar aprotic solvent
- an appropriate base such as, for example, an alkali metal carbonate or hydrogen carbonate, sodium hydride or an organic base may be utilized to pick up the acid which is liberated during the course of the reaction. Somewhat elevated temperatures may enhance the rate of the reaction.
- reaction of (XII) with (XIII), or (XIV) with (I-d-8) can generally be conducted in a suitable reaction-inert solvent such as, for example, an ether, e.g., tetrahydrofuran and the like, a halogenated hydrocarbon, e.g., trichloromethane and the like. Elevated temperatures may be suitable to enhance the rate of the reaction.
- a suitable reaction-inert solvent such as, for example, an ether, e.g., tetrahydrofuran and the like, a halogenated hydrocarbon, e.g., trichloromethane and the like. Elevated temperatures may be suitable to enhance the rate of the reaction.
- the compounds of formula ⁇ ) wherein L is a radical of formula (b-3), Z 2 is a direct bond, Z 1 is other than a direct bond and T is other than NR 9 , said Z* ⁇ and T being represented by Z*- * ⁇ a and T 2 , said compounds being represented by (I-d-9), can be prepared by reacting a compound of formula (I-d-8) with a reagent of formula (XV) or a reactive functional derivative thereof.
- the reaction of (XV) with (I-d-8) may generally be conducted following art-known esterif ⁇ cation or amidation reaction procedures.
- the carboxylic acid may be converted into a reactive derivative, e.g., an anhydride or a carboxylic acid halide, which subsequently is reacted with (I-d-8); or by reacting (XV) and (I-d-8) with a suitable reagent capable of forming amides or esters, e.g., N,N-methanetetraylbis- [cyclohexamine], 2-chloro-l-methylpy ⁇ idinium iodide and the like.
- Said reactions may most conveniently be conducted in a suitable solvent such as, for example, an ether, e.g., tetrahydrofuran, a halogenated hydrocarbon, e.g., dichloromethane, trichloromethane, a dipolar aprotic solvent, e.g. N,N-dimethylformamide, and the like.
- a suitable solvent such as, for example, an ether, e.g., tetrahydrofuran, a halogenated hydrocarbon, e.g., dichloromethane, trichloromethane, a dipolar aprotic solvent, e.g. N,N-dimethylformamide, and the like.
- a base such as, for example, N,N-diethylethanamine and the like may be appropriate.
- the compounds of formula (I) wherein R3, R ⁇ or R-5 are Het may also be prepared following art-known procedures for preparing heterocyclic ring systems or following analogous methods.
- a number of such cyclization procedures are described in for example, US-4,695,575 and in the references cited therein, in particular US-4,335,127; US-4,342,870 and US-4,443,451.
- the compounds of formula (I) can also be converted into each other following art- known procedures of functional group transformation. Some examples of such procedures are cited hereinafter.
- the compounds of formula (I) containing a cyano substituent can be converted into the corresponding amines by stirring and, if desired, heating the starting cyano compounds in a hydrogen containing medium in the presence of an appropriate catalyst such as, for example, platinum-on-charcoal, Raney nickel and the like catalysts.
- Suitable solvents are, for example, methanol, ethanol and the like.
- the compounds of formula (I) containing an amino group can also be obtained by hydrolysis of the corresponding carbamate derivative in acidic medium.
- Amino groups may be alkylated or acylated following art-known procedures such as, for example, M-alkylation, N-acylation, reductive _N[-alkylation and the like methods.
- reaction products may be isolated from the reaction mixture and, if necessary, further purified according to methodologies generally known in the art
- the intermediates of formula (Il-a), (Ill-a) and (IH-b) wherein L is hydrogen and n is 1, said intermediates being represented by (II-a-2), ( ⁇ I-a-2) and (HI-b-2), can be obtained from reduction of the pyridine ring of a compound of formula (XVIE-a), (XVm-b) and (XVIII-c), respectively.
- the intermediates of formula (XVHI-a), (XVTJI-b) and (XVIII-c) can be reduced by catalytic hydrogenation in a suitable solvent e.g. methanol, ethanol, or acetic acid, in the presence of hydrogen and an appropriate catalyst, e.g. rhodium-on-charcoal and the like, optionally at an increased temperature and/or pressure.
- a suitable solvent e.g. methanol, ethanol, or acetic acid
- an appropriate catalyst e.g. rhodium-on-charcoal and the like
- said compounds of formula (XNQI-a), (XN ⁇ i-b) and (XVIII-c) may be reduced by an alkali metal in liquid ammonia, preferably in the presence of an alcohol (Birch reduction).
- the intermediates of formula (XVTfl-a) and (XVEH-b) can be prepared by reacting a compound of formula (XLX), wherein R 16 is H or methyl, with an intermediate of formula (XX) in the presence of a base, in a reaction-inert solvent
- R 16 CH 3 : (XV ⁇ i-b)
- Suitable bases are, for example, potassium tert butoxide, n. butyllithium, sodium amide, sodium hydride or lithium diisopropylamide.
- Reaction-inert solvents are, for example, ethers, e.g. tetrahydrofuran, 1,4-dioxane and the like.
- the intermediates of formula (XX) can be prepared by catalytic hydrogenolysis of the halo compound of formula (XXI), in a suitable solvent e.g. methanol or ethanol, in the presence of hydrogen and an appropriate catalyst, e.g. platinum-on-charcoal, palladium- on-charcoal and the like, and in the presence of a suitable base, e.g. calcium oxide, calcium carbonate and the like, optionally at an increased temperature and/or pressure.
- a suitable solvent e.g. methanol or ethanol
- an appropriate catalyst e.g. platinum-on-charcoal, palladium- on-charcoal and the like
- a suitable base e.g. calcium oxide, calcium carbonate and the like, optionally at an increased temperature and/or pressure.
- Pure stereochemically isomeric forms of the compounds of formula (I) may be obtained by the application of art-known procedures. Diastereoisomers may be separated by physical methods such as selective crystallization and chromatographic techniques, e.g. counter current distribution, liquid chromatography and the like; and enantiomers may be separated from each other following art-known resolution methods, for example, by the selective crystallization of their diastereomeric salts with chiral acids. Pure stereochemically isomeric forms may also be derived from the corresponding pure stereochemically isomeric forms of the appropriate starting materials, provided that the reactions occur stereospecifically. Preferably, if a specific stereoisomer is desired, said compound will be synthesized by stereoselective methods of preparation. These methods will advantageously employ enantiomerically pure starting materials.
- the compounds of formula (I), the pharmaceutically acceptable acid addition salts and stereochemically isomeric forms thereof possess useful pharmacological properties. More particularly, they are active antihistaminics which can clearly be demonstrated by, e.g. the results obtained in the test "Protection of Rats from Compound 48/80-induced lethality". Surprisingly, some of the present compounds have improved anti-histaminic activity over structurally related compounds wherein X ⁇ Q — is CH— CH 2 — ,
- the compounds of formula ( ) and their acid addition salts are very useful in the treatment of allergic diseases such as, for example, allergic rhinitis, allergic conjunctivitis, chronic urticaria, allergic asthma and the like.
- the subject compounds may be formulated into various pharmaceutical forms for administration purposes.
- an effective amount of the particular compound, in base or acid addition salt form, as the active ingredient is combined in intimate admixture with a pharmaceutically acceptable carrier, which carrier may take a wide variety of forms depending on the form of preparation desired for administration.
- a pharmaceutically acceptable carrier which carrier may take a wide variety of forms depending on the form of preparation desired for administration.
- These pharmaceutical compositions are desirably in unitary dosage form suitable, preferably, for administration orally, rectally, percutaneously, or by parenteral injection.
- any of the usual pharmaceutical media may be employed such as, for example, water, glycols, oils, alcohols and the like in the case of oral liquid preparations such as suspensions, syrups, elixirs and solutions: or solid carriers such as starches, sugars, kaolin, lubricants, binders, disintegrating agents and the like in the case of powders, pills, capsules and tablets. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are obviously employed.
- the carrier will usually comprise sterile water, at least in large part, though other ingredients, for example to aid solubility, may be included.
- Injectable solutions may be prepared in which the carrier comprises saline solution, glucose solution or a mixture of saline and glucose solution. Injectable suspensions may also be prepared in which case appropriate liquid carriers, suspending agents and die like may be employed.
- the carrier optionally comprises a penetration enhancing agent and/or a suitable wetting agent, optionally combined with suitable additives of any nature in minor proportions, which additives do not introduce a significant deleterious effect on the skin. Said additives may facilitate the administration to die skin and/or may be helpful for preparing the desired compositions.
- These compositions may be administered in various ways, e.g., as a transdermal patch, as a spot-on or as an ointment. Acid addition salts of (I) due to their increased water solubility over the corresponding base form, are obviously more suitable in the preparation of aqueous compositions.
- Dosage unit form as used in the specification and claims herein refers to physically discrete units suitable as unitary dosages, each unit containing a predetermined quantity of active ingredient calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier.
- dosage unit forms are tablets (including scored or coated tablets), capsules, pills, powder packets, wafers, injectable solutions or suspensions, teaspoonfuls, tablespoonfuls and the like, and segregated multiples thereof.
- the present invention also relates to a method of treating warm-blooded animals suffering from said allergic diseases by administering to said warm-blooded animals an antiallergically effective amount of a compound of formula (I) or a pharmaceutically acceptable acid addition salt form thereof.
- an antiallergically effective amount would be from about 0.001 mg/kg to about 20 mg/kg body weight and more preferably from about 0.01 mg kg to about 5 mg/kg body weight.
- Example 2 a) A mixture of 10 parts of 2-chloro-l-[(4-fluorophenyl)methyl]-lH-benzimidazole, 3 parts of calciumoxide and 200 parts of methanol was hydrogenated at normal pressure and room temperature in the presence of 2 parts of palladium-on-charcoal catalyst 10%. After the calculated amount of hydrogen was taken up, the catalyst was filtered off and the filtrate was evaporated. The residue was dissolved in trichloromethane and this solution was washed witii water, dried, filtered and evaporated. The residue was crystallized from a mixture of 2,2'-oxybispropane and petroleumether.
- Example 3 A mixture of 2 parts of intermediate (5) and 15 parts of polyphosphoric acid was stirred for 1 hour at 150-160°C. After cooling to 100°C, the reaction mixture was carefully diluted with water. Next there was added NaOH (aq.) while cooling on ice. The product was extracted wit 4-methyl-2-pentanone and the extract was dried, filtered and evaporated. The residue was purified by column chromatography (silica gel ; CHCI 3 / CH 3 OH(NH3) 95:5). The eluent of the desired fraction was evaporated and die residue was converted into die (E)-2-butenedioate salt in ethanol.
- Example 8 A mixture of 3.35 parts of compound (1), 1 part of polyoxymethylene and 120 parts of methanol was hydrogenated at normal pressure and room temperature in the presence of 2 parts of palladium-on-charcoal catalyst 10%. After the calculated amount of hydrogen was taken up, the catalyst was filtered off and die filtrate was evaporated. The residue was purified by column chromatography (silica gel ; CHCI3 / CH3OH(NH3) 95:5). The eluent of the desired fraction was evaporated and the residue was converted into die hydrochloride salt in 2,2'-oxybispropane by addition of 2-propanol saturated witii HCl.
- Example 15 A mixture of 1.03 parts of isotiiiocyanatomethane, 3.6 parts of compound (27) and 90 parts of tetrahydrofuran was stirred for 6 hours at room temperature. The reaction mixture was evaporated and die residue was diluted witii water. The product was extracted with trichloromethane and the extract was dried, filtered and evaporated. The residue was purified by column chromatography (silica gel ; CHCI 3 / CH3OH 90:10). The eluent of the desired fraction was evaporated and the residue was converted into die cyclohexanesulfamate salt in 2-propanone.
- Active ingredient as used diroughout these examples relates to a compound of formula (I), a pharmaceutically acceptable acid addition salt or a stereochemically isomeric form thereof.
- 500 g of the A.I. is dissolved in 0.5 1 of 2-hydroxypropanoic acid and 1.51 of the polyediylene glycol at 60 ⁇ 80°C. After cooling to 30 ⁇ 40°C there are added 351 of polyethylene glycol and die mixture is stirred well. Then there is added a solution of 1750 g of sodium saccharin in 2.51 of purified water and while stirring there are added 2.51 of cocoa flavor and polyethylene glycol q.s. to a volume of 501, providing an oral drop solution comprising 10 mg/ml of the A.I. The resulting solution is filled into suitable containers.
- Example 18 Oral solutions 9 g of metiiyl 4-hydroxybenzoate and 1 g of propyl 4-hydroxybenzoate are dissolved in 41 of boding purified water. In 3 1 of this solution are dissolved first 10 g of 2,3-dihydroxybutanedioic acid and thereafter 20 g of the A.I. The latter solution is combined widi the remaining part of the former solution and 121 of 1,2,3-propanetriol and 31 of sorbitol 70% solution are added tiiereto. 40 g of sodium saccharin are dissolved in 0.51 of water and 2 ml of raspberry and 2 ml of gooseberry essence are added. The latter solution is combined with die former, water is added q.s. to a volume of 201 providing an oral solution comprising 5 mg of the A.I. per teaspoonful (5 ml). The resulting solution is filled in suitable containers.
- Example 20 Film-coated tablets
- a mixture of 100 g of die A.I., 570 g lactose and 200 g starch is mixed well and tiiereafter humidified widi a solution of 5 g sodium dodecyl sulfate and 10 g polyvinyl- pyrrolidone (Kollidon-K 90®) in about 200 ml of water.
- the wet powder mixture is sieved, dried and sieved again.
- tiiere are added 100 g microcrystalline cellulose (Avicel®) and 15 g hydrogenated vegetable oil (Sterotex ®). The whole is mixed well and compressed into tablets, giving 10.000 tablets, each comprising 10 mg of die active ingredient. ga ing
- Example 22 Suppositories 3 g A.I. is dissolved in a solution of 3 g 2,3-dihydroxybutanedioic acid in 25 ml polyethylene glycol 400. 12 g surfactant (SPAN®) and triglycerides (Witepsol 555®) q.s. ad 300 g are molten togetiier. The latter mixture is mixed well widi die former solution. The thus obtained mixture is poured into moulds at a temperature of 37-38°C to form 100 suppositories each containing 30 mg of the A.I.
- Suppositories 3 g A.I. is dissolved in a solution of 3 g 2,3-dihydroxybutanedioic acid in 25 ml polyethylene glycol 400. 12 g surfactant (SPAN®) and triglycerides (Witepsol 555®) q.s. ad 300 g are molten togetiier. The latter mixture is mixed
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
On décrit des dérivés de 4-pipéridinyle antihistaminiques de formule (I), dans laquelle α représente (d-3); (d-1); ou (d-2); =A?1-A2=A3-A4¿= représente =CH-CH=CH-CH=, =CH-N=CH-CH=, =CH-CH=N-CH=, 1CH-CH=CH-N=, =N-CH=N-CH= ou =CH-N=CH-N; R1 représente Ar ou -D-R2 dans lequel D représente O ou S; R2 représente alkyle C¿1-6? éventuellement substitué avec hydroxy, alkyloxy C1-6, carboxyle ou alkyloxycarbonyle C1-6; m est égal à 1, 2, 3 ou 4; m vaut 0, 1 ou 2; L représente hydrogène, alkyle C1-12; cycloalkyle C3-6; alcényle C3-6 éventuellement substitué avec aryle; alkylcarbonyle C1-6; alkyloxycarbonyle; arylcarbonyle; aryle C1-6; alkyloxycarbonyle; arylcarbonyle; aryle C1-6alkyloxycarbonyle; ou radical -Alk-R?3¿; -alk-Y-R4; -Alk-Z1-C-(=T)-Z?2-R5; -CH¿2-CHOH-0CH2-O-R6. On décrit également un procédé de préparation de ces dérivés. De plus, l'invention se rapporte aux compositions contenant lesdits composés antihistaminiques et à un procédé de traitement des maladies allergiques.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP92200041.9 | 1992-01-09 | ||
EP92200041 | 1992-01-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1993014083A1 true WO1993014083A1 (fr) | 1993-07-22 |
Family
ID=8210355
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1992/003006 WO1993014083A1 (fr) | 1992-01-09 | 1992-12-29 | Derives de benzimidazole substitues pharmaceutiquement actifs |
Country Status (5)
Country | Link |
---|---|
AU (1) | AU3347493A (fr) |
IL (1) | IL104347A0 (fr) |
TW (1) | TW231291B (fr) |
WO (1) | WO1993014083A1 (fr) |
ZA (1) | ZA93144B (fr) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997024324A1 (fr) * | 1995-12-27 | 1997-07-10 | Janssen Pharmaceutica N.V. | Derives 1-(piperidinyl 1,2-disubstitue)-4-substitue-piperidine comme antagonistes des recepteurs de la tachykinine |
US6706720B2 (en) | 1999-12-06 | 2004-03-16 | Bristol-Myers Squibb Company | Heterocyclic dihydropyrimidine compounds |
US7160879B2 (en) | 2002-01-10 | 2007-01-09 | Neurogen Corporation | Melanin concentrating hormone receptor ligands: substituted 2-(4-benzyl-piperazin-1-ylmethyl)- and 2-(4-benzyl-diazepan-1-ylmethyl)-1H-benzoimidazole analogues |
US7772232B2 (en) | 2004-04-15 | 2010-08-10 | Bristol-Myers Squibb Company | Quinazolinyl compounds as inhibitors of potassium channel function |
US8604200B2 (en) | 2005-03-08 | 2013-12-10 | Janssen Pharmaceutica N.V. | Diaza-spiro-{4,4}-nonane derivatives as neurokinin (NK1) antagonists |
JP2015519381A (ja) * | 2012-06-11 | 2015-07-09 | ユーシービー バイオファルマ エスピーアールエル | Tnf−アルファ調節ベンゾイミダゾール |
US10705094B2 (en) | 2015-06-18 | 2020-07-07 | UCB Biopharma SRL | TNF receptor signaling modulator assay |
US11174311B2 (en) | 2016-12-21 | 2021-11-16 | UCB Biopharma SRL | Antibody against trimeric TNFα complex |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0151826A1 (fr) * | 1984-01-09 | 1985-08-21 | Janssen Pharmaceutica N.V. | Pipéridines méthyl-4 dont le groupe méthyl est substitué par un groupe hétérocyclique bicylique et pipéridines avec un hétéroatome lié en position 4 et substitué par un groupe hétérocyclique |
EP0282133A2 (fr) * | 1987-03-09 | 1988-09-14 | Janssen Pharmaceutica N.V. | Dérivés de benzimidazole substitués en 1 par alkyle |
EP0363963A1 (fr) * | 1988-10-13 | 1990-04-18 | Merrell Dow Pharmaceuticals Inc. | Benzimidazoles pipéridinyliques comme antihistaminiques |
EP0378254A2 (fr) * | 1989-01-09 | 1990-07-18 | Janssen Pharmaceutica N.V. | Dérivés de 2-aminopyrimidinone |
-
1992
- 1992-12-29 WO PCT/EP1992/003006 patent/WO1993014083A1/fr active Application Filing
- 1992-12-29 TW TW081110419A patent/TW231291B/zh active
- 1992-12-29 AU AU33474/93A patent/AU3347493A/en not_active Abandoned
-
1993
- 1993-01-08 IL IL104347A patent/IL104347A0/xx unknown
- 1993-01-08 ZA ZA93144A patent/ZA93144B/xx unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0151826A1 (fr) * | 1984-01-09 | 1985-08-21 | Janssen Pharmaceutica N.V. | Pipéridines méthyl-4 dont le groupe méthyl est substitué par un groupe hétérocyclique bicylique et pipéridines avec un hétéroatome lié en position 4 et substitué par un groupe hétérocyclique |
EP0282133A2 (fr) * | 1987-03-09 | 1988-09-14 | Janssen Pharmaceutica N.V. | Dérivés de benzimidazole substitués en 1 par alkyle |
EP0363963A1 (fr) * | 1988-10-13 | 1990-04-18 | Merrell Dow Pharmaceuticals Inc. | Benzimidazoles pipéridinyliques comme antihistaminiques |
EP0378254A2 (fr) * | 1989-01-09 | 1990-07-18 | Janssen Pharmaceutica N.V. | Dérivés de 2-aminopyrimidinone |
Cited By (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997024324A1 (fr) * | 1995-12-27 | 1997-07-10 | Janssen Pharmaceutica N.V. | Derives 1-(piperidinyl 1,2-disubstitue)-4-substitue-piperidine comme antagonistes des recepteurs de la tachykinine |
US6169097B1 (en) | 1995-12-27 | 2001-01-02 | Janssen Pharmaceutica N.V. | 1-(1,2-Disubstituted piperidinyl)-4-substituted piperidine derivatives |
EA001559B1 (ru) * | 1995-12-27 | 2001-04-23 | Жансен Фармасетика Н.В. | Производные 1-(1,2-дизамещенный пиперидинил)-4-замещенного пиперидина как антагонисты рецепторов тахикинина |
US6346540B1 (en) | 1995-12-27 | 2002-02-12 | Janssen Pharmaceutica N.V. | 1-(1,2-disubstituted pipeidinyl)-4-substituted piperidine derivatives |
CN1131854C (zh) * | 1995-12-27 | 2003-12-24 | 詹森药业有限公司 | 作为速激肽受体拮抗剂的1-(1,2-二取代哌啶基)-4-取代哌啶衍生物 |
US6706720B2 (en) | 1999-12-06 | 2004-03-16 | Bristol-Myers Squibb Company | Heterocyclic dihydropyrimidine compounds |
US7157451B2 (en) | 1999-12-06 | 2007-01-02 | Bristol-Myers Squibb Company | Heterocyclic dihydropyrimidine compounds |
US7541362B2 (en) | 1999-12-06 | 2009-06-02 | Bristol-Myers Squibb Company | Heterocyclic dihydropyrimidine compounds |
US7160879B2 (en) | 2002-01-10 | 2007-01-09 | Neurogen Corporation | Melanin concentrating hormone receptor ligands: substituted 2-(4-benzyl-piperazin-1-ylmethyl)- and 2-(4-benzyl-diazepan-1-ylmethyl)-1H-benzoimidazole analogues |
US8357704B2 (en) | 2004-04-15 | 2013-01-22 | Bristol-Myers Squibb Company | Fused heterocyclic compounds as inhibitors of potassium channel function |
US7772232B2 (en) | 2004-04-15 | 2010-08-10 | Bristol-Myers Squibb Company | Quinazolinyl compounds as inhibitors of potassium channel function |
US8604200B2 (en) | 2005-03-08 | 2013-12-10 | Janssen Pharmaceutica N.V. | Diaza-spiro-{4,4}-nonane derivatives as neurokinin (NK1) antagonists |
JP2015519381A (ja) * | 2012-06-11 | 2015-07-09 | ユーシービー バイオファルマ エスピーアールエル | Tnf−アルファ調節ベンゾイミダゾール |
US9550737B2 (en) | 2012-06-11 | 2017-01-24 | Ucb Biopharma Sprl | TNF -α modulating benzimidazoles |
US10883996B2 (en) | 2015-06-18 | 2021-01-05 | UCB Biopharma SRL | Methods of identifying signaling modulators of the trimeric TNFa |
US10775385B2 (en) | 2015-06-18 | 2020-09-15 | UCB Biopharma SRL | Treatment of autoimmune and inflammatory disorders with asymmetric TNF alpha trimers |
US10705094B2 (en) | 2015-06-18 | 2020-07-07 | UCB Biopharma SRL | TNF receptor signaling modulator assay |
US10969393B2 (en) | 2015-06-18 | 2021-04-06 | UCB Biopharma SRL | Complexes between anti-TNF antibodies, trimeric TNF proteins and organic molecules binding them |
US11022614B2 (en) | 2015-06-18 | 2021-06-01 | UCB Biopharma SRL | Antibodies binding to trimeric TNF alpha epitopes |
US11448655B2 (en) | 2015-06-18 | 2022-09-20 | UCB Biopharma SRL | Method for identifying a modulator of the TNFα or CD40L interaction with their cognate receptors |
US11674967B2 (en) | 2015-06-18 | 2023-06-13 | UCB Biopharma SRL | Method of identifying potential inhibitors of APO TNFα trimers |
US12055549B2 (en) | 2015-06-18 | 2024-08-06 | UCB Biopharma SRL | Methods of use of anti-TNFα antibodies |
US11174311B2 (en) | 2016-12-21 | 2021-11-16 | UCB Biopharma SRL | Antibody against trimeric TNFα complex |
Also Published As
Publication number | Publication date |
---|---|
AU3347493A (en) | 1993-08-03 |
ZA93144B (en) | 1994-07-08 |
TW231291B (fr) | 1994-10-01 |
IL104347A0 (en) | 1993-05-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4804663A (en) | 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles | |
EP0232937B1 (fr) | Compositions anti-histaminiques contenant des N-hétérocyclyl-4-pipéridinamines | |
KR0184017B1 (ko) | 이미다조[2,1-b][3]벤즈아제핀 유도체,조성물 및 사용방법 | |
US5086056A (en) | 2-(heterocyclylalkyl)imidazopyridines | |
US4835161A (en) | Anti-histaminic compositions containing n-heterocyclyl-4-piperidinamines | |
US4988689A (en) | ((Pharmacologically active bicyclic heterocyclic)methyl and -heteroatom) substituted hexahydro-1H-azepines and pyrrolidines | |
US5932569A (en) | Triazolobenzazepine derivatives | |
RU2067978C1 (ru) | Замещенные тиазолильные и замещенные пиридинильные производные или их фармацевтически приемлемые кислотно-аддитивные соли, способ их получения и композиция, обладающая антиаллергической активностью | |
US5008268A (en) | 2-aminopyrimidinone derivatives | |
US4897401A (en) | N-(4-piperidinyl) bicyclic condensed 2-imidazolamine derivatives useful in treating allergic diseases | |
WO1992006086A1 (fr) | Nouveaux derives de 4-piperidinylcarbonyle | |
EP0297661A1 (fr) | [(Hétérocyclyl bicyclique) méthyl et -hétéro]hexahydro-1H-azépines et -pyrrolidines | |
WO1993014083A1 (fr) | Derives de benzimidazole substitues pharmaceutiquement actifs | |
EP0393738B1 (fr) | Dérivés hydroxyalkylfuranyliques | |
US5272150A (en) | Hydroxyalkylfuranyl derivatives | |
JPH03153686A (ja) | (6,7―ジヒドロ―5H―ピロロ[1,2―c]イミダゾリ―5―ル)―および(5,6,7,8―テトラヒドロイミダゾ[1,5―a]ピリジニ―5―ル)置換された1H―ベンゾトリアゾール誘導体 | |
US5066656A (en) | Pharmacologically active (6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl)- and (5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl) substituted 1H-benzotriazole derivatives | |
US5151424A (en) | Pharmacologically active (Bicyclic heterocyclyl)methyl and -hetero) substituted hexahydro-1H-azepines and pyrrolidines | |
NZ258552A (en) | Azepine derivatives; compounds, preparation of and pharmaceutical compositions containing such compounds | |
US5006527A (en) | Pharmacologically active N-(4-piperidinyl) bicyclic condensed 2-imidazolamine derivatives | |
US5071846A (en) | Anti-hystaminic [(bicyclic heterocyclyl) methyl and --hetero] substituted hexahydro-1H-azepines and pyrrolidines | |
EP0714395A1 (fr) | Dihydropyranopyridines substituees vasoconstrictrices | |
WO1993014088A1 (fr) | Derives de piperazinyle |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU BB BG BR CA CS FI HU JP KP KR LK MG MN MW NO NZ PL PT RO RU SD US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: CA |